Patents by Inventor Binhao ZHANG

Binhao ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230373972
    Abstract: The present disclosure relates to a piperazine derivative, a preparation method therefor, and use thereof in medicine. Specifically, the present invention relates to a piperazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutically acceptable salt or prodrug thereof, and use thereof as a therapeutic agent, in particular, as an inhibitor of coagulation factor XIa (FXIa), wherein the definition of each substituent in general formula (I) is the same as that in the description.
    Type: Application
    Filed: September 16, 2021
    Publication date: November 23, 2023
    Applicants: Zhejiang Hisun Pharmaceutical Co., Ltd., Shanghai Aryl Pharmtec Co., Ltd.
    Inventors: Haibo QIU, Yutao MA, Ahuan CHEN, Yabo ZHU, Binhao ZHANG, Yongping LU, Cheng YE, Taishan HU, Wenjian QIAN, Lei CHEN
  • Methods for establishing animal model of hepatocellular carcinoma bone metastasis
    Patent number: 9807986
    Abstract: A method for establishing an animal model of hepatocellular carcinoma (HCC) bone metastasis, the method including: 1) establishing 97H and LM3 cell clones with stable expression of firefly luciferase (LUC); 2) allowing HCC cells to form bone metastasis in nude mice via intratibial injection; 3) reproducing HCC bone metastasis in nude mice via intracardiac injection of tumor cells; and 4) isolating a sub-population of tumor cells that targets metastasis to bone. The 97H and the LM3 are highly metastatic HCC cell lines transfected with luciferase gene. BALB/cA-nu mice are 4-5 weeks old and maintained in laminar flow cabinets under SPF conditions and received human care throughout an entire study. A cell number for intratibial injection is 0.5×106, and a cell number for intracardiac injection is 1×106.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: November 7, 2017
    Inventors: Rui Hou, Yuwei Wang, Huifang Liang, Zhanguo Zhang, Zhimin Liu, Binhao Zhang, Bixiang Zhang, Xiaoping Chen
  • METHODS FOR ESTABLISHING ANIMAL MODEL OF HEPATOCELLULAR CARCINOMA BONE METASTASIS
    Publication number: 20170273283
    Abstract: A method for establishing an animal model of hepatocellular carcinoma (HCC) bone metastasis, the method including: 1) establishing 97H and LM3 cell clones with stable expression of firefly luciferase (LUC); 2) allowing HCC cells to form bone metastasis in nude mice via intratibial injection; 3) reproducing HCC bone metastasis in nude mice via intracardiac injection of tumor cells; and 4) isolating a sub-population of tumor cells that targets metastasis to bone. The 97H and the LM3 are highly metastatic HCC cell lines transfected with luciferase gene. BALB/cA-nu mice are 4-5 weeks old and maintained in laminar flow cabinets under SPF conditions and received human care throughout an entire study. A cell number for intratibial injection is 0.5×106, and a cell number for intracardiac injection is 1×106.
    Type: Application
    Filed: March 28, 2016
    Publication date: September 28, 2017
    Inventors: Rui HOU, Yuwei WANG, Huifang LIANG, Zhanguo ZHANG, Zhimin LIU, Binhao ZHANG, Bixiang ZHANG, Xiaoping CHEN